leisure time -WSS

leisure time

author：hotspot 2025-09-30 04:34:48 - browse：878

AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

AstraZeneca will pay Pfizer up to $1 billion plus royalties for the portfolio of treatments, none of which has entered clinical trials yet. The companies did not say how much it is paying upfront.

The moves come six months after Pfizer said it would stop much of its work on early-stage gene therapy programs, in which researchers try to deliver replacement genes encased in small, non-pathogenic bugs called adeno-associated viruses, or AAVs. Instead, it would focus on newer technologies, such as gene editing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： Lawsuit alleges UnitedHealth Group unit illegally denied claims

knowledge

WSS

Guidelines to prevent youth baseball injuries need more muscle

Malaria cases in Florida and Texas: Here’s what you need to know

Scientists inch closer to single

Guidelines to prevent youth baseball injuries need more muscle

Physician groups backed by private equity giant lobby on mergers

United colonoscopy coverage change 'may cost lives,' doctors say

hotspot

leisure time

focus

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Peter Hotez and the public health issue of online harassment

Alkermes shareholders re

State Dept. review finds Biden bears some blame for Afghanistan failures

23andMe had bad news about my health. I wish a person had delivered it

Bright Health sells Medicare Advantage business to Molina

What the airline industry can learn from medicine

Tori Bowie and the unacceptable rates of Black maternal death

Trump indictment: Who are the 'co

focus

Adults seen as increasingly susceptible to measles

Mitch McConnell episode has important public health takeaway

The high personal cost of affirmative action for Black doctors

How to save PrEP access — and even expand it

‘Oppenheimer’ and the risks of AI in health care

New safety details link Apellis eye drug to rare cases of blindness

leisure time

hotspot

knowledge

explore